The treatment of marginal zone lymphoma.

However, few advances have occurred in marginal zone lymphoma (MZL), with a single US Food and Drug Administration-approved agent impacting the treatment landscape.

然而，在边缘区淋巴瘤（MZL）领域，进展甚少，唯一影响治疗格局的是美国食品药品监督管理局批准的一种药物。

Multiple factors are associated with this slower pace of progress, with a lower MZL incidencerepresenting a significant factor.

多种因素与这种进展缓慢的步伐有关，较低的边缘区淋巴瘤（MZL）发病率是一个重要因素。

Pivotal randomized indolent lymphoma clinical trials analyzed MZL subsets without the appropriate power to capture differences between treatment arms.

关键的随机惰性淋巴瘤临床试验分析了MZL亚组，但没有足够的能力捕捉治疗组之间的差异。

Furthermore, the current Lugano classification may not fully capture the presentation or treatment responses of some subtypes, preventing access to clinical trials and limiting an efficacy assessment across the disease spectrum.

此外，现行的Lugano分类可能无法完全涵盖某些亚型的表现或治疗反应，这限制了进入临床试验的机会，并限制了对疾病谱系的疗效评估。

Thus, current MZL treatment is largely informed by single-arm studies with relatively empiric treatment sequencing among available agents.

因此，目前的MZL治疗主要基于单臂研究，以及在可用药物之间相对经验性的治疗序列。

Although frontline strategies in early and advanced-stage MZL can achieve prolonged disease control, few options exist in the relapsed/refractory setting capable of achieving similar results.

尽管在早期和晚期边缘区淋巴瘤（MZL）的一线治疗策略能够实现疾病控制的延长，但在复发/难治性环境中，能够取得类似结果的治疗选项却很少。

Emerging data demonstrate the encouraging efficacy of CD3×CD20 bispecific antibodies and antibody-drug conjugates in achieving deep responses, as well as the potential of circulating tumor DNA in risk stratification and molecular response monitoring.

新兴数据展示了CD3×CD20双特异性抗体和抗体药物偶联物在实现深度反应方面的令人鼓舞的疗效，以及循环肿瘤DNA在风险分层和分子反应监测中的潜力。

Compounding all these considerations, it is essential to recognize MZL as a heterogeneous group of diseases characterized by unique biology, clinical presentation, treatment response, toxicity, and survival. Nonetheless, a common characteristic across MZL subtypes is their general indolent disease course, emphasizing the need to incorporate patient-centered assessment in clinical trials to better inform the decision-making process.

综合所有这些因素，必须认识到MZL是一组异质性疾病，其特点是独特的生物学特性、临床表现、治疗反应、毒性和生存率。然而，MZL亚型的一个共同特征是它们通常具有惰性病程，这强调了在临床试验中纳入以患者为中心的评估的必要性，以更好地指导决策过程。